Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer

Nair, J; Huang, TT; Murai, J; Haynes, B; Steeg, PS; Pommier, Y; Lee, JM

Nair, J (corresponding author), NIH, Womens Malignancies Branch, Bldg 10, Bethesda, MD 20892 USA.

ONCOGENE, 2020; 39 (33): 5520